Dermapharm Holding (ETR:DMP) Full Year 2024 Results

Key Financial Results

Revenue: €1.20b (up 3.9% from FY 2023). Net income: €113.8m (up 82% from FY 2023). Profit margin: 9.5% (up from 5.4% in FY 2023). EPS: €2.11 (up from €1.16 in FY 2023).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.XTRA:DMP Revenue and Expenses Breakdown April 4th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Dermapharm Holding Revenues Beat Expectations

Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) was mostly in line with analyst estimates.

The primary driver behind last 12 months revenue was the Branded Pharmaceuticals segment contributing a total revenue of €587.9m (49% of total revenue). The largest operating expense was General & Administrative costs, amounting to €287.4m (45% of total expenses).  Explore how DMP's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany.

Performance of the German Pharmaceuticals industry.

The company's shares are down 4.2% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Dermapharm Holding that you should be aware of before investing here.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments